The first national audit for rheumatoid and early inflammatory arthritis has benchmarked care for the first 3 months of follow-up activity from first presentation to a rheumatology service. Access to care, management of early rheumatoid arthritis and support for self care were measured against National Institute for Health and Care Excellence quality standards; impact of early arthritis and experience of care were measured using patient-reported outcome and experience measures. The results demonstrate delays in referral and accessing specialist care and the need for service improvement in treating to target, suppression of high levels of disease activity and support for self-care. Improvements in patient-reported outcomes within 3 months and high levels of overall satisfaction were reported but these results were affected by low response rates. This article presents a summary of the national data from the audit and discusses the implications for nursing practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941919 | PMC |
| http://dx.doi.org/10.12968/bjon.2016.25.11.613 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Mendelian randomization study of alcohol use and cardiometabolic disease risk in a multi-ancestry population from the Million Veteran Program.
Alcohol Clin Exp Res (Hoboken)
December 2024
Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Article Synopsis
Efficacy and safety of integrated traditional Chinese and Western medicine for rheumatoid arthritis-interstitial lung disease: A systematic review and meta-analysis.
Heliyon
November 2024
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Objective: To systematically evaluate the efficacy and safety of integrated traditional Chinese and Western medicine(TCM-WM) for the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Materials And Methods: An independent search of electronic databases (PubMed, Excerpta Medica Database, Cochrane Central Register of Controlled Trials, OVID Medline, China National Knowledge Infrastructure, WanFang Data, VIP Data databases, and China Biology Medicine disc) from inception to June 25, 2024 was performed to identify studies treating RA-ILD that used combined Chinese and Western medicine treatment compared to Western medicine. Two researchers independently audited each article, and the quality was assessed using the Cochrane Risk of Bias Assessment Tool 2 and the modified Jadad.
Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort study.
Rheumatology (Oxford)
November 2024
Centre for Rheumatic Diseases, King's College London, London, UK.
Objective: To evaluate temporal and regional variation in biologic and targeted synthetic DMARD (b/tsDMARD) initiation for rheumatoid arthritis (RA) in England and Wales.
Methods: An observational cohort study was conducted for people with RA enrolled in the National Early Inflammatory Arthritis Audit (NEIAA) between May 2018 and April 2022 who had 12-month follow-up data. Temporal trends in escalation to b/tsDMARDs within 12 months of initial rheumatology assessment were explored, including comparisons before and after publication (July 2021) of national guidelines that lowered the threshold for b/tsDMARD initiation to include moderate-severity RA.
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study.
Lancet Rheumatol
January 2025
Centre for Rheumatic Diseases, King's College London, London, UK.
Article Synopsis
- * The study used data from the National Early Inflammatory Arthritis Audit and included 6098 patients in England and Wales, focusing on those diagnosed between May 2018 and April 2022, analyzing factors influencing the initiation of DMARD treatments within 12 months of their first appointment.
- * Results showed that only 8.3% of patients started DMARDs in that timeframe, with younger patients (under 40) being significantly more likely to begin treatment compared to older patients over 65, highlighting age-related disparities in accessing care.
Time to start disease modifying drugs for adults with seropositive rheumatoid arthritis: results of the first year of the national New Zealand Rheumatology Association (NZRA) audit.
N Z Med J
August 2024
Consultant Rheumatologist and Clinical Director, Rheumatology Department, Waikato Hospital, Hamilton.
Article Synopsis
- - The audit investigates how long it takes patients with newly diagnosed seropositive rheumatoid arthritis (RA) to start disease modifying drug (DMARD) treatment and whether this timing meets the recommended 6 weeks.
- - Data from 355 patients showed that 64.8% started DMARD treatment within the target timeframe, with significant correlations to rheumatologist staffing levels and the rurality of the patients.
- - The study concluded that variations in the time to DMARD treatment are largely influenced by the number of rheumatologists available and the geographic location of the patients, rather than factors like ethnicity or socio-economic status.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!